A treatable traits approach for asthma in a post-COVID era

Abstract

As a novel respiratory viral infection, coronavirus disease 2019 (COVID-19) has influenced asthma in unpredictable ways. In the post-COVID era, there is a need to review asthma care and the new challenges and opportunities that are presented. Long COVID is a new and complex syndrome that has arisen. Treatable traits (TTs) have already been developed to address complex asthma and can be adapted to manage long COVID. Consumers are seeking more information on and answers to what to expect with a dual diagnosis of asthma and COVID-19. People with asthma identify a strong need for research into COVID and asthma. Completion of a national survey (n=593) resulted in a list of research themes. From these, participants prioritized 10 asthma research themes. Among the top 10 asthma research priorities, the theme of COVID and asthma was ranked as the second priority in the overall rank list. Addressing these issues has the potential to improve global asthma health.

Keywords

Asthma / COVID / treatable traits / long COVID / clinicians

References

[1] Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci. 2020; 57: 365-88.

[2] Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020; 13: 667-73.

[3] Verhoeven E, Rouadi P, Jaoude EA, Abouzakouk M, Ansotegui I, Al-Ahmad M, et al. Digital tools in allergy and respiratory care. World Allergy Organ J. 2022; 15: 100661.

[4] Wosik J, Fudim M, Cameron B, Gellad ZF, Cho A, Phinney D, et al. Telehealth transformation: COVID-19 and the rise of virtual care. J Am Med Inform Assoc. 2020; 27: 957-62.

[5] Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998; 351: 1225-32.

[6] Davies GA, Alsallakh MA, Sivakumaran S, Vasileiou E, Lyons RA, Robertson C, et al. ; EAVE II Collaborators. Impact of COVID-19 lockdown on emergency asthma admissions and deaths: national interrupted time series analyses for Scotland and Wales. Thorax. 2021; 76: 867-73.

[7] Shah SA, Quint JK, Nwaru BI, Sheikh A. Impact of COVID-19 national lockdown on asthma exacerbations: interrupted time-series analysis of English primary care data. Thorax. 2021; 76: 860-6. Erratum in: Thorax. 2023;78:e3.

[8] Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2 . J Allergy Clin Immunol. 2020; 146: 203-6.e3.

[9] Sajuthi SP, DeFord P, Li Y, Jackson ND, Montgomery MT, Everman JL, et al. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. Nat Commun. 2020; 11: 5139.

[10] Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. 2020; 146: 80-8.e8.

[11] Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids. Am J Respir Crit Care Med. 2020; 202: 83-90. Erratum in: Am J Respir Crit Care Med. 2020; 202:1744-6.

[12] Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ ; COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020; 395: 1973-87.

[13] Bloom CI. Covid-19 pandemic and asthma: What did we learn? Respirology. 2023; 28: 603-14.

[14] Hazan G, Fox C, Mok H, Haspel J. Age-dependent rebound in asthma exacerbations after COVID-19 lockdown. J Allergy Clin Immunol Glob. 2022; 1: 314-8.

[15] Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, et al. After asthma: redefining airways diseases. Lancet. 2018; 391: 350-400.

[16] Post COVID-19 condition (Long COVID) [Internet]. Geneva: World Health Organization; c2024 [cited 2024 Mar 7]. Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-COVID-19-condition

[17] Census Bureau, Household Pulse Survey, 2022-2024. Long COVID [Internet]. Atlanta: Centers for Disease Control and Prevention; [cited 2024 Mar 7]. Available from: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm

[18] Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016; 47: 410-9.

[19] McDonald VM, Fingleton J, Agusti A, Hiles SA, Clark VL, Holland AE, et al. ; participants of the Treatable Traits Down Under International Workshop. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. Eur Respir J. 2019; 53: 1802058.

[20] Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica GW, et al. Interleukin-5 in the Pathophysiology of Severe Asthma. Front Physiol. 2019; 10: 1514.

[21] George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016; 7: 34-51.

[22] Nelson RK, Bush A, Stokes J, Nair P, Akuthota P. Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2020; 8: 465-73.

[23] The severe asthma toolkit [Internet]. Newcastle: Centre of Excellence in Severe Asthma; c2018 [cited 2024 Mar 7]. Available from: https://toolkit.severeasthma.org.au/

[24] Centre of Excellence in Severe Asthma homepage [Internet]. Newcastle: Centre of Excellence in Severe Asthma; c2016 [cited 2024 Mar 7]. Available from: https://www.severeasthma.org.au/

[25] Centre of excellence in treatable traits homepage [Internet]. Newcastle: Centre of Excellence in Treatable Traits; c2024 [cited 2024 Mar 7]. Available from: https://treatabletraits.org.au/

[26] Duszyk K, McLoughlin RF, Gibson PG, McDonald VM. The use of treatable traits to address COPD complexity and heterogeneity and to inform the care. Breathe. 2021; 17: 210118.

[27] Clark VL, Gibson PG, Genn G, Hiles SA, Pavord ID, McDonald VM. Multidimensional assessment of severe asthma: A systematic review and meta-analysis. Respirology. 2017; 22: 1262-75.

[28] Sarwar MR, McDonald VM, Abramson MJ, McLoughlin RF, Geethadevi GM, George J. Effectiveness of Interventions Targeting Treatable Traits for the Management of Obstructive Airway Diseases: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2022; 10: 2333-45.e21.

[29] McDonald VM, Clark VL, Cordova-Rivera L, Wark PAB, Baines KJ, Gibson PG. Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J. 2020; 55: 1901509.

[30] Agusti A, Gibson PG, McDonald VM. Treatable Traits in Airway Disease: From Theory to Practice. J Allergy Clin Immunol Pract. 2023; 11: 713-23.

[31] Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020; 55: 1902420.

[32] McDonald VM, Gibson PG. Treatable traits and their application in high-, middle- and low-income countries. Respirology. 2019; 24: 942-3.

[33] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. ; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382: 727-33.

[34] COVID-19 rapid guideline: managing the long-term effects of COVID-19 [Internet]. London: National Institute for Health and Care Excellence; c2024 [cited 2023 July 6]. Available from: https://www.nice.org.uk/guidance/ng188

[35] A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus, 16 February 2023 [Internet]. Geneva: World Health Organization; c2024 [cited 2023 July 6]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-condition-CA-Clinical-case-definition-2023-1

[36] Long COVID or Post-COVID Conditions [Internet]. Atlanta: Centers for Disease Control and Prevention; [cited 2023 July 6]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html

[37] Munblit D, O’Hara ME, Akrami A, Perego E, Olliaro P, Needham DM. Long COVID: aiming for a consensus. Lancet Respir Med. 2022; 10: 632-4.

[38] Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022; 226: 1593-607.

[39] Lampl BMJ, Leitzmann MF, Salzberger B. Prevalence of Post-COVID-19 Conditions Depends on the Method of Assessment. J Infect Dis. 2023; 227: 306.

[40] Fernández-de-Las-Peñas C. Long COVID: current definition. Infection. 2022; 50: 285-6.

[41] O’Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2022; 55: 101762. Erratum in: EClinicalMedicine. 2023;59:101959.

[42] Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. ; TLC Study Group. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021; 114: 428-42.

[43] Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022; 28: 657-66.

[44] Perumal R, Shunmugam L, Naidoo K, Abdool Karim SS, Wilkins D, Garzino-Demo A, et al. Long COVID: a review and proposed visualization of the complexity of long COVID. Front Immunol. 2023; 14: 1117464.

[45] Carfì A, Bernabei R, Landi F ; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020; 324: 603-5.

[46] Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Florencio LL, Cuadrado ML, Plaza-Manzano G, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. Eur J Intern Med. 2021; 92: 55-70.

[47] Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J Med Virol. 2022; 94: 253-62.

[48] Han Q, Zheng B, Daines L, Sheikh A. Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms. Pathogens. 2022; 11: 269.

[49] Poudel AN, Zhu S, Cooper N, Roderick P, Alwan N, Tarrant C, et al. Impact of Covid-19 on health-related quality of life of patients: A structured review. PLoS One. 2021; 16: e0259164.

[50] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023; 21: 133-46. Erratum in: Nat Rev Microbiol. 2023; 21:408.

[51] Su S, Zhao Y, Zeng N, Liu X, Zheng Y, Sun J, et al. Epidemiology, clinical presentation, pathophysiology, and management of long COVID: an update. Mol Psychiatry. 2023; 28: 4056-69.

[52] Natarajan A, Shetty A, Delanerolle G, Zeng Y, Zhang Y, Raymont V, et al. A systematic review and meta-analysis of long COVID symptoms. Syst Rev. 2023; 12: 88.

[53] Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023; 23: 618-34. Erratum in: Nat Rev Immunol. 2023; 23:697.

[54] De Domenico M. Prevalence of long COVID decreases for increasing COVID-19 vaccine uptake. PLOS Glob Public Health. 2023; 3: e0001917.

[55] Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. JAMA. 2022; 328: 676-8.

[56] Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022; 28: 1461-7.

[57] Ora J, Calzetta L, Frugoni C, Puxeddu E, Rogliani P. Expert guidance on the management and challenges of long-COVID syndrome: a systematic review. Expert Opin Pharmacother. 2023; 24: 315-30.

[58] Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022; 53: 101624.

[59] Mantovani A, Morrone MC, Patrono C, Santoro MG, Schiaffino S, Remuzzi G, et al. ; Covid-19 Commission of the Accademia Nazionale dei Lincei. Long Covid: where we stand and challenges ahead. Cell Death Differ. 2022; 29: 1891-900.

[60] Norton A, Olliaro P, Sigfrid L, Carson G, Paparella G, Hastie C, et al. ; ISARIC and GloPID-R Long COVID Forum Working Group. Long COVID: tackling a multifaceted condition requires a multidisciplinary approach. Lancet Infect Dis. 2021; 21: 601-2. Erratum in: Lancet Infect Dis. 2021; 21:e81.

[61] Antoniou KM, Vasarmidi E, Russell AM, Andrejak C, Crestani B, Delcroix M, et al. European Respiratory Society statement on long COVID follow-up. Eur Respir J. 2022; 60: 2102174.

[62] Ashra F, Jen HJ, Liu D, Lee TY, Pien LC, Chen R, et al. Effectiveness of respiratory rehabilitation in patients with COVID-19: A meta-analysis. J Clin Nurs. 2023; 32: 4972-87.

[63] Parker AM, Brigham E, Connolly B, McPeake J, Agranovich AV, Kenes MT, et al. Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care. Lancet Respir Med. 2021; 9: 1328-41.

[64] Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. Risk Factors Associated With Post−COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA Intern Med. 2023; 183: 566-80.

[65] Wang L, Foer D, Zhang Y, Karlson EW, Bates DW, Zhou L. Post-Acute COVID-19 Respiratory Symptoms in Patients With Asthma: An Electronic Health Records-Based Study. J Allergy Clin Immunol Pract. 2023; 11: 825-35.e3.

[66] Philip KEJ, Buttery S, Williams P, Vijayakumar B, Tonkin J, Cumella A, et al. Impact of COVID-19 on people with asthma: a mixed methods analysis from a UK wide survey. BMJ Open Respir Res. 2022; 9: e001056.

[67] Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. ; IVY Network Investigators; CDC COVID-19 Response Team; IVY Network Investigators. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 993-8.

[68] Healey Q, Sheikh A, Daines L, Vasileiou E. Symptoms and signs of long COVID: A rapid review and meta-analysis. J Glob Health. 2022; 12: 05014.

[69] Rochmawati E, Iskandar AC, Kamilah F. Persistent symptoms among post-COVID-19 survivors: A systematic review and meta-analysis. J Clin Nurs. 2024; 33: 29-39.

[70] Song WJ, Hui CKM, Hull JH, Birring SS, McGarvey L, Mazzone SB, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med. 2021; 9: 533-44.

[71] Kang YR, Huh JY, Oh JY, Lee JH, Lee D, Kwon HS, et al. Clinical Characteristics of Post-COVID-19 Persistent Cough in the Omicron Era. Allergy Asthma Immunol Res. 2023; 15: 395-405.

[72] Lee H, Kim BG, Chung SJ, Park DW, Park TS, Moon JY, et al. New-onset asthma following COVID-19 in adults. J Allergy Clin Immunol Pract. 2023; 11: 2228-31.

[73] Hastie CE, Lowe DJ, McAuley A, Mills NL, Winter AJ, Black C, et al. Natural history of long-COVID in a nationwide, population cohort study. Nat Commun. 2023; 14: 3504.

[74] Hastie CE, Lowe DJ, McAuley A, Winter AJ, Mills NL, Black C, et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun. 2022; 13: 5663. Erratum in: Nat Commun. 2022; 13:6540.

[75] Ionescu MF, Mani-Babu S, Degani-Costa LH, Johnson M, Paramasivan C, Sylvester K, et al. Cardiopulmonary Exercise Testing in the Assessment of Dysfunctional Breathing. Front Physiol. 2021; 11: 620955.

[76] Gibson PG, McDonald VM, Granchelli A, Olin JT. Asthma and Comorbid Conditions-Pulmonary Comorbidity. J Allergy Clin Immunol Pract. 2021; 9: 3868-75.

[77] Boulding R, Stacey R, Niven R, Fowler SJ. Dysfunctional breathing: a review of the literature and proposal for classification. Eur Respir Rev. 2016; 25: 287-94.

[78] Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: Clinical impact and management. Respirology. 2017; 22: 651-61.

[79] Bondarenko J, Holland AE. Clinimetrics: The Breathing Pattern Assessment Tool. J Physiother. 2023; 69: 127.

[80] Frésard I, Genecand L, Altarelli M, Gex G, Vremaroiu P, Vremaroiu-Coman A, et al. Dysfunctional breathing diagnosed by cardiopulmonary exercise testing in ‘long COVID’ patients with persistent dyspnoea. BMJ Open Respir Res. 2022; 9: e001126.

[81] Hylton H, Long A, Francis C, Taylor RR, Ricketts WM, Singh R, et al. Real-world use of the Breathing Pattern Assessment Tool in assessment of breathlessness post-COVID-19. Clin Med (Lond). 2022; 22: 376-9.

[82] Lewthwaite H, Byrne A, Brew B, Gibson PG. Treatable traits for long COVID. Respirology. 2023; 28: 1005-22.

[83] Romanet C, Wormser J, Fels A, Lucas P, Prudat C, Sacco E, et al. Effectiveness of exercise training on the dyspnoea of individuals with long COVID: A randomised controlled multicentre trial. Ann Phys Rehabil Med. 2023; 66: 101765.

[84] Del Corral T, Fabero-Garrido R, Plaza-Manzano G, Fernández-de-Las-Peñas C, Navarro-Santana M, López-de-Uralde-Villanueva I. Home-based respiratory muscle training on quality of life and exercise tolerance in long-term post-COVID-19: Randomized controlled trial. Ann Phys Rehabil Med. 2023; 66: 101709.

[85] McNarry MA, Berg RMG, Shelley J, Hudson J, Saynor ZL, Duckers J, et al. Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial. Eur Respir J. 2022; 60: 2103101.

[86] Majellano EC, Bell RL, Flynn AW, Mckenzie A, Sivamalai S, Goldman M, et al. Identifying the asthma research priorities of people with asthma, their carers and other stakeholders. Respirology. 2023; 28: 636-48.

[87] Adeloye D, Elneima O, Daines L, Poinasamy K, Quint JK, Walker S, et al. ; International COVID-19 Airways Diseases Group. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respir Med. 2021; 9: 1467-78.

[88] Houchen-Wolloff L, Poinasamy K, Holmes K, Tarpey M, Hastie C, Raihani K, et al. Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19. Thorax. 2022; 77: 717-20.

[89] The Lancet Respiratory Medicine. Personalised medicine for asthma in a post-pandemic world. Lancet Respir Med. 2021; 9: 1.

[90] Collins-Fairclough A, Barn P, Hirsch-Allen AJ, Rideout K, Shellington EM, Lo W, et al. Disparities in self-reported healthcare access for airways disease in British Columbia, Canada, during the COVID-19 pandemic. Insights from a survey co-developed with people living with asthma and chronic obstructive pulmonary disease. Chron Respir Dis. 2023; 20: 1-11.

[91] McDonald VM, Holland AE. Treatable traits models of care. Respirology. 2024; 29: 24-35.